{"id":"hmg-subcutaneous-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Gallstones"},{"rate":"5-10%","effect":"Diabetes mellitus"},{"rate":"5-10%","effect":"Scoliosis"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle weakness"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by replacing the body's natural growth hormone to stimulate growth and development in children with growth hormone deficiency. The exact mechanism of action is not fully understood, but it is believed to involve the stimulation of growth plates in bones and the regulation of growth hormone receptors.","oneSentence":"hMG subcutaneous injection is a recombinant human growth hormone used to treat growth hormone deficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:00.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"}]},"trialDetails":[{"nctId":"NCT03209687","phase":"PHASE4","title":"The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-07-06","conditions":"Infertility","enrollment":600},{"nctId":"NCT07216742","phase":"PHASE3","title":"Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.","status":"RECRUITING","sponsor":"Granata Bio Corporation","startDate":"2025-11-01","conditions":"Infertility (IVF Patients)","enrollment":659},{"nctId":"NCT05567731","phase":"NA","title":"Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-15","conditions":"Intracytoplasmic Sperm Injection, GnRH Agonist, Infertility","enrollment":30},{"nctId":"NCT04608474","phase":"PHASE4","title":"Lipid Management in Renal Transplant Recipients Using Evolocumab.","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-17","conditions":"Hyperlipidemias","enrollment":120},{"nctId":"NCT04071574","phase":"PHASE1, PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":"Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure","enrollment":200},{"nctId":"NCT01380730","phase":"PHASE2","title":"LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-01","conditions":"Hyperlipidemia","enrollment":631},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT02634580","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-27","conditions":"Hypercholesterolemia","enrollment":61},{"nctId":"NCT01763905","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-24","conditions":"Hyperlipidemia","enrollment":307},{"nctId":"NCT03750760","phase":"PHASE4","title":"Early Alirocumab to Reduce LDL-C in Myocardial Infarction","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2020-01","conditions":"Myocardial Infarction, Dyslipidemias","enrollment":""},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT03684824","phase":"NA","title":"Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2018-09","conditions":"Invitro Fertilization","enrollment":100},{"nctId":"NCT02766764","phase":"PHASE4","title":"Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2016-06","conditions":"Subfertility","enrollment":230},{"nctId":"NCT02979886","phase":"NA","title":"Effects of SNP of GnRH Receptor Genes in IVF Patients","status":"UNKNOWN","sponsor":"Miao benyu","startDate":"2017-01","conditions":"Infertility, Female","enrollment":1500},{"nctId":"NCT02640976","phase":"EARLY_PHASE1","title":"Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program","status":"COMPLETED","sponsor":"Cairo University","startDate":"2013-06","conditions":"Infertility","enrollment":216},{"nctId":"NCT01604044","phase":"PHASE1","title":"Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2012-05","conditions":"Female Infertility","enrollment":579},{"nctId":"NCT01417195","phase":"PHASE4","title":"Menopur Mixed Protocol","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-07","conditions":"Infertility","enrollment":122},{"nctId":"NCT01487486","phase":"","title":"Proteomics & Glyco-Proteomic Analysis of Follicular Fluid","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2011-12","conditions":"Polycystic Ovary Syndrome, Normal Volunteers","enrollment":30},{"nctId":"NCT00802360","phase":"PHASE4","title":"MENOPUR® Versus FOLLISTIM®","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2008-12","conditions":"Infertility","enrollment":173},{"nctId":"NCT00257556","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-10","conditions":"Infertility","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"hMG subcutaneous injection","genericName":"hMG subcutaneous injection","companyName":"Granata Bio Corporation","companyId":"granata-bio-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"hMG subcutaneous injection is a recombinant human growth hormone used to treat growth hormone deficiency. Used for Growth hormone deficiency in children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}